Results 141 to 150 of about 16,299 (214)

Circulating neprilysin hypothesis

open access: yes
Circulating Neprilysin (sNEP) has emerged as a potential prognostic biomarker in heart failure (HF). In PARAGON-HF benefit of sacubitril/valsartan was only observed in patients with left ventricular ejection fraction (LVEF) ≤57%. We aimed to assess the prognostic value of sNEP in outpatients with HF and LVEF >57%, in comparison with patients with LVEF ≤
Lupón, Josep||   +10 more
openaire   +1 more source

Bleeding Disorder, A Newly Recognized Adverse Event Following Sacubitril/Valsartan Therapy. [PDF]

open access: yesEur J Case Rep Intern Med
Al-Omari YW   +3 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy